| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 77.0 | ¤1,057,104 | US |
| JNJ | Johnson & Johnson | 51.6 | ¤566,130 | US |
| MRK | Merck & Co., Inc. | 54.7 | ¤284,449 | US |
| AZN | AstraZeneca PLC | 63.8 | ¤277,155 | GB |
| AMGN | Amgen Inc. | 62.2 | ¤187,732 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| THC | Tenet Healthcare Corporation | 67.1 | ¤15,811 | US |
| STE | STERIS plc | 65.8 | ¤20,126 | IE |
| DGX | Quest Diagnostics Incorporated | 56.1 | ¤22,254 | US |
| UTHR | United Therapeutics Corporation | 64.4 | ¤23,272 | US |
| RMD | ResMed Inc. | 67.4 | ¤28,132 | US |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 62.2 | 32 | US |
| LLY | Eli Lilly and Company | 77.0 | 27 | US |
| PFE | Pfizer Inc. | 48.0 | 25 | US |
| DGX | Quest Diagnostics Incorporated | 56.1 | 23 | US |
| ZTS | Zoetis, Inc. Class A | 60.2 | 23 | US |
| BMY | Bristol-Myers Squibb Company | 61.9 | 22 | US |
| JNJ | Johnson & Johnson | 51.6 | 22 | US |
| RMD | ResMed Inc. | 67.4 | 20 | US |
| GILD | Gilead Sciences, Inc. | 71.5 | 19 | US |
| UTHR | United Therapeutics Corporation | 64.4 | 18 | US |
| Average Market Cap | ¤132,562 |
| Median Market Cap | ¤53,333 |
| Avg. 3 Mo. Dollar Vol. | ¤651,622,713 |
| Avg. 3 Mo. Trading Vol. | 4,677,968 |
| Last Rebalance Date | 03/23/2026 |
| Companies Replaced | 7 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 24.2 |
| Forward P/E Ratio (12 Mo.) | 18.1 |
| Price/Book Ratio | 5.2 |
| Avg. Revenue Chg. - 3 Yr | 20.6% |
| Avg. Op. Income Chg. - 3 Yr. | 33.8% |
| Avg. EPS Growth - 3 Yr. | 15.4% |
| Avg. EPS Growth - 1 Yr. | 11.4% |
| Avg. Operating Margin | 23.2% |
| Avg. LT Debt to Total Capital | 41.7% |
| Avg. Return on Equity | 22.7% |
| Dividend Yield | 0.6% |
| US Health Care Index | 61.9 |
| United States Of America | 90.0% |
| Switzerland | 3.33% |
| United Kingdom | 3.33% |
| Ireland | 3.33% |
